Naturally Splendid Enterprises

Naturally Splendid Grants Options to Buy 1.28M Shares

Naturally Splendid Enterprises Ltd. ("Naturally Splendid" or "NSE" or the "Company") (FRANKFURT:50N) (TSX-V:NSP) (OTC:NSPDF) announces that it has issued stock options. The Company has granted 1,285,000 stock options to its directors, advisors and employees. The options were granted at an exercise price of $0.10 for a period of five (5) years, vesting immediately and expiring 5 years from date of grant.

About Naturally Splendid Enterprises Ltd.

Naturally Splendid is a plant-based food manufacturing and technology company that produces and distributes nutritious and delicious plant-based commodity products.

Founded in 2010, the Company operates a certified food manufacturing facility located just outside Vancouver, BC in Canada, focusing on producing an extensive range of plant-based entrees.

Naturally Splendid has an exclusive 10-year manufacturing and distribution agreement for Canada with a division of Australia's largest plant-based food manufacturer, Flexitarian Foods Pty. Ltd.

In addition to producing the Company's own branded products, Naturally Splendid provides contract manufacturing services and private labelling for a variety of nutritional plant-based food products destined for multiple distribution channels.

The Company has established healthy, functional foods under brands such as Natera Sport, Natera Hemp Foods, CHIITM, Elevate MeTM and Woods Wild BarTM. The Company launched PlanteinTM Plant-Based Foods, a line of delicious plant-based meat alternatives for the rapidly growing plant-based market segment.

Naturally Splendid has reached an agreement with Biologic to terminate the agreement with Plasm Pharmaceutical and is negotiating a compensation package for work done to date pursuing a potential treatment for Covid with the target drug Cavaltinib.

NSE has also developed proprietary technologies for the extraction of healthy omega 3 and 6 oils, as well as a protein concentrate from hemp.

On Behalf of the Board of Directors

Mr. J. Craig Goodwin
President, Director

Forward-Looking Statements

Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management's current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. Naturally Splendid cautions that all forward looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many Naturally Splendid Enterprises, Ltd. #108-19100 Airport Way, Pitt Meadows, BC V3Y 0E2 Tel: 604-570-0902 Email: info@naturallysplendid.com Website: www.naturallysplendid.com of which are beyond Naturally Splendid's control including, Naturally Splendid's ability to compete with large food and beverage companies; sales of any potential products developed will be profitable; sales of shelled hemp seed will continue at existing rates or increase; customers will complete on sales contracts; and the risk that any of the potential applications may not receive all required regulatory or legal approval. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, Naturally Splendid undertakes no obligation to publicly update or revise forward-looking information.

NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Source

Click here to connect with Naturally Splendid Enterprises Ltd. (FRANKFURT:50N, TSX-V:NSP, OTC:NSPDF), to receive an Investor Presentation

NSP:CA
The Conversation (0)
Naturally Splendid Reports Third Quarter Results for 2022 and Company Update

Naturally Splendid Reports Third Quarter Results for 2022 and Company Update

Naturally Splendid Enterprises Ltd. ("Naturally Splendid", "NSE" or "the Company") (FRANKFURT:50N)(TSXV:NSP)(OTC PINK:NSPDF) announces its unaudited financial results for the nine months ended September 30, 2022. All amounts are in Canadian dollars and are prepared in accordance with International Financial Reporting Standards

Naturally Splendid CEO Mr. Craig Goodwin states, "As we continue to focus our efforts and resources on PlanteinTM Plant-Based Foods and our ten (10) year exclusive manufacturing and distribution agreement with Flexitarian Foods PTY Ltd., there have been many positives as well as a number of challenges. The positives include our recent launch into retail, and the return to trade shows where are products have been getting exceptional reviews, as well as our expanding relations with our national distributors. However, the Company has experienced significant challenges as well, the most notable being the continued delay of customized manufacturing lines being assembled in Shanghai, China. The delay to date has been due to a combination of shortage of computer chips, combined with on-going Covid challenges and subsequent quarantining in Shanghai".

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Naturally Splendid Management Update

Naturally Splendid Management Update

Naturally Splendid Enterprises Ltd. ("Naturally Splendid", "NSE" or "the Company") (FRANKFURT:50N)(TSXV:NSP)(OTC PINK:NSPDF) announces that Mr. George Ragogna will be stepping down as CFO and a Member of the Board of Directors effective immediately

Mr. Ragogna will remain with the Company as an Independent Consultant, focusing his efforts on logistics and our inventory management control system. Mr. Bryan Carson, current Executive VP and Company Co-founder, will step in as interim CFO.

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Naturally Splendid Presents at Grocery Innovations Canada Trade Show in Toronto

Naturally Splendid Presents at Grocery Innovations Canada Trade Show in Toronto

Naturally Splendid Enterprises Ltd. ("Naturally Splendid", "NSE" or "the Company") (FRANKFURT:50N)(TSXV:NSP)(OTC PINK:NSPDF) is pleased to announce the Company presented the PlanteinTM line of plant-based entrees at the Grocery Innovations Canada trade show on October 25 and October 26, 2022, at the Toronto Congress Centre

Grocery Innovations Canada, is one of Canada's premier grocery trade show events, bringing together manufacturers and retailers from not only Eastern Canada, but in fact from all across the country. Naturally Splendid featured the PlanteinTM line of plant-based products to retailers and distributors from across the country.

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Vegan Supply to Distribute Plantein Through Foodservice Network & Sell in Retail Store

Vegan Supply to Distribute Plantein Through Foodservice Network & Sell in Retail Store

VANCOUVER, BC / ACCESSWIRE/ September 6, 2022 / Naturally Splendid Enterprises Ltd. ("Naturally Splendid", "NSE" or "the Company") (FRANKFURT:50N)(TSXV:NSP)(OTC Pink:NSPDF) is pleased to announce that Vegan Supply will carry a selection of PlanteinTM products for its retail and foodservice customers.

Vegan Supply, a Vancouver based company with both retail and foodservice distribution, began business in 2015 as the world's largest e-commerce marketplace exclusively providing their retail customers and foodservice clients with high-quality vegan products. Vegan Supply is listing five (5) PlanteinTM plant-based entrees: Nuggets, Schnitzel, Crumbed Tenders, Sweet Chili Tenders, and Crispy Burgers. The PlanteinTM line of products will be available through Vegan Supply's retail store in Vancouver, BC, their e-commerce platform, and marketed to their foodservice distribution network.

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
CORRECTION: Naturally Splendid Reports Second Quarter Results for 2022

CORRECTION: Naturally Splendid Reports Second Quarter Results for 2022

This release acts as a correction for the release posted on 8/29/2022 at 10:30 PM EDT from Naturally Splendid Enterprises Ltd. announcing its second quarter results for 2022 due to an error in comments stated

Naturally Splendid Enterprises Ltd. ("Naturally Splendid", "NSE" or "the Company") (FRANKFURT:50N)(TSXV:NSP)(OTC PINK:NSPDF) announces its unaudited financial results for the six months ended June 30, 2022. All amounts are in Canadian dollars and are prepared in accordance with International Financial Reporting Standards

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Sirona Biochem (TSXV:SBM)

Sirona Biochem


Keep reading...Show less
Young female researcher working in a lab.

Radiopharmaceuticals Take Investors to the Forefront of Precision Oncology

Radiopharmaceuticals are emerging as one of the most promising innovations in modern medicine, particularly in precision oncology, and if recent billion-dollar investment deals are any indication, the potential for growth can be significant. Investors eyeing exposure to this emerging technology would benefit from a deeper understanding of the technology, its strategic applications and investment opportunities.

A groundbreaking technology in the field of oncology, radiopharmaceuticals combine radioactive substances with targeted molecules to revolutionise cancer detection and treatment. These innovative compounds are gaining significant attention due to their ability to deliver precise and targeted cancer therapies, minimising damage to healthy tissues while maximising therapeutic efficacy.

At their core, radiopharmaceuticals leverage the unique properties of radioactive isotopes, pairing them with molecules that have a high affinity for cancer cells. This combination allows for both diagnostic imaging and therapeutic applications, offering a level of precision previously unattainable in traditional cancer treatments.

Keep reading...Show less
Sirona Biochem Announces Publication of Groundbreaking Study on TFC-1326 Compound in the Journal of Cosmetic Dermatology

Sirona Biochem Announces Publication of Groundbreaking Study on TFC-1326 Compound in the Journal of Cosmetic Dermatology

Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) is proud to announce the publication of a pivotal research article in the prestigious Journal of Cosmetic Dermatology .

About the Study

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

AMGEN ANNOUNCES SENIOR EXECUTIVE RESEARCH APPOINTMENT

Howard Chang , M.D., Ph.D.,   Joins as Senior Vice President of Research and Chief Scientific Officer

Amgen (NASDAQ:AMGN) today announced that Howard Chang M.D., Ph.D., will join the company as senior vice president of Research, effective Dec. 16, 2024 . Chang will also assume the title and responsibility of serving as Amgen's chief scientific officer, reporting to Jay Bradner M.D., executive vice president of Research and Development.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Top 5 Life Science ETFs in 2024

Top 5 Life Science ETFs in 2024

Taking a position in a life science exchange-traded fund (ETF) provides exposure to a basket of stocks focused on the healthcare sector, while mitigating the risks of holding shares in a single company.

While ETFs provide diversification by their nature, fund managers often narrow down their offerings to follow a specific aspect of the market — for example, biotech or pharma. They also typically adjust the weight of ETF holdings to match movements in the life science industry in an effort to give investors the best possible returns.

There are many choices when it comes to life science ETFs, and to help investors understand their options, the Investing News Network has listed the top life science ETFs by year-on-year performance.

Keep reading...Show less
Radiopharm Theranostics

Australian Ethics Committee Approval to Expand PD-L1 Nanobody (RAD204) Phase 1 Trial in Multiple Tumor Types

Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce it has been granted Human Research Ethics Committee (HREC) approval to include participants with Programmed Death-Ligand 1 (PD-L1) positive Small Cell Lung Cancer (SCLC), Triple Negative Breast Cancer (TNBC), Melanoma, Head and Neck Cancer (HNSCC), and Endometrial Cancer, as part of its ongoing Phase 1 clinical trial of 177Lu-labelled RAD204 for the treatment of PD-L1 expressing cancers.
Keep reading...Show less

Latest Press Releases

Related News

×